tradingkey.logo

Anteris Technologies Global Corp

AVR
查看详细走势图
5.490USD
+0.270+5.17%
收盘 02/06, 16:00美东报价延迟15分钟
197.98M总市值
亏损市盈率 TTM

Anteris Technologies Global Corp

5.490
+0.270+5.17%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+5.17%

5天

-8.04%

1月

+13.43%

6月

+51.66%

今年开始到现在

+10.02%

1年

-11.45%

查看详细走势图

操作建议

Anteris Technologies Global Corp当前公司基本面数据相对健康,最新ESG披露属于行业领先水平。增长潜力稳定。当前估值合理,在医疗设备与耗材行业排名98/205位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价15.00。中期看,股价处于上升通道。近一个月,市场表现很强,技术面评分较高,但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Anteris Technologies Global Corp评分

相关信息

行业排名
98 / 205
全市场排名
261 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Anteris Technologies Global Corp亮点

亮点风险
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
业绩增长期
公司处于发展阶段,最新年度总收入2.70M美元
利润高增长
公司净利润处于行业前列,最新年度总收入2.70M美元
估值合理
公司最新PE估值-2.35,处于3年历史合理位
机构加仓
最新机构持股25.19M股,环比增加5.38%
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值2.04K

分析师目标

根据 4 位分析师
买入
评级
15.000
目标均价
+173.22%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Anteris Technologies Global Corp新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Anteris Technologies Global Corp简介

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
公司代码AVR
公司Anteris Technologies Global Corp
CEOPaterson (Wayne G)
网址https://anteristech.com/
KeyAI